Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
6
|
| pubmed:dateCreated |
1992-7-14
|
| pubmed:abstractText |
The efficacy of combined high-dose etoposide with standard dose cisplatin was evaluated in patients who had refractory lung cancer after standard chemotherapy. Each patient was given etoposide at 500 mg/m2/day on day 1 to 3 continuously (total dose 1,500 mg/m2) and cisplatin at 80 mg/m2 on day 1. Fifteen patients (7 adenocarcinoma, 5 small cell lung cancer, 2 squamous cell lung cancer and 1 sarcoma, which latter was difficult to distinguish from giant cell carcinoma) were entered in this study. The overall response was 41.7% (5 of 12); five partial response, 6 no change, and 1 progressive disease. Three treatment-related deaths were observed; one resulted from sepsis and two from respiratory failure because of tumor progression. All of the patients developed severe myelosuppression; the mean nadir white blood cell count was 400, and the mean nadir platelet count was 24,000 in 28 evaluable courses. The range of maximum concentration of etoposide determined by HPLC was from 17.4 to 39.1 micrograms/ml. These results suggest that high-dose etoposide combined with a standard dose of cisplatin is effective against refractory lung cancer.
|
| pubmed:language |
jpn
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jun
|
| pubmed:issn |
0385-0684
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
19
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
849-54
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:1318697-Adenocarcinoma,
pubmed-meshheading:1318697-Adult,
pubmed-meshheading:1318697-Aged,
pubmed-meshheading:1318697-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:1318697-Carcinoma, Small Cell,
pubmed-meshheading:1318697-Carcinoma, Squamous Cell,
pubmed-meshheading:1318697-Cisplatin,
pubmed-meshheading:1318697-Drug Administration Schedule,
pubmed-meshheading:1318697-Drug Evaluation,
pubmed-meshheading:1318697-Etoposide,
pubmed-meshheading:1318697-Female,
pubmed-meshheading:1318697-Humans,
pubmed-meshheading:1318697-Lung Neoplasms,
pubmed-meshheading:1318697-Lymphatic Metastasis,
pubmed-meshheading:1318697-Male,
pubmed-meshheading:1318697-Middle Aged,
pubmed-meshheading:1318697-Neoplasm Metastasis,
pubmed-meshheading:1318697-Pilot Projects,
pubmed-meshheading:1318697-Sarcoma
|
| pubmed:year |
1992
|
| pubmed:articleTitle |
[Pilot phase II trial of high-dose etoposide combined with cisplatin in the treatment of refractory lung cancer].
|
| pubmed:affiliation |
First Dept. of Internal Medicine, Kagawa Medical School.
|
| pubmed:publicationType |
Journal Article,
English Abstract
|